[go: up one dir, main page]

EP1601357A4 - HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS - Google Patents

HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS

Info

Publication number
EP1601357A4
EP1601357A4 EP04719237A EP04719237A EP1601357A4 EP 1601357 A4 EP1601357 A4 EP 1601357A4 EP 04719237 A EP04719237 A EP 04719237A EP 04719237 A EP04719237 A EP 04719237A EP 1601357 A4 EP1601357 A4 EP 1601357A4
Authority
EP
European Patent Office
Prior art keywords
synthesis
methods
kinase inhibitors
heterocyclic kinase
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04719237A
Other languages
German (de)
French (fr)
Other versions
EP1601357A1 (en
Inventor
M Arshad Siddiqui
David Belanger
Chaoyang Dai
Lianyun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1601357A1 publication Critical patent/EP1601357A1/en
Publication of EP1601357A4 publication Critical patent/EP1601357A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04719237A 2003-03-10 2004-03-10 HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS Withdrawn EP1601357A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US453457P 2003-03-10
US46091003P 2003-04-07 2003-04-07
US460910P 2003-04-07
US46302503P 2003-04-15 2003-04-15
US463025P 2003-04-15
US50271003P 2003-09-12 2003-09-12
US502710P 2003-09-12
PCT/US2004/007286 WO2004080463A1 (en) 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis

Publications (2)

Publication Number Publication Date
EP1601357A1 EP1601357A1 (en) 2005-12-07
EP1601357A4 true EP1601357A4 (en) 2007-10-03

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04719237A Withdrawn EP1601357A4 (en) 2003-03-10 2004-03-10 HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS

Country Status (5)

Country Link
EP (1) EP1601357A4 (en)
JP (1) JP2006519846A (en)
CA (1) CA2518398A1 (en)
MX (1) MXPA05009722A (en)
WO (1) WO2004080463A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
MX2007011453A (en) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Dipeptidyl peptidase-iv inhibitors.
EP1931657B1 (en) 2005-08-17 2013-12-25 Merck Sharp & Dohme Corp. Novel high affinity quinoline-based kinase ligands
DK3421471T3 (en) 2006-04-25 2021-06-14 Astex Therapeutics Ltd PURIN AND DEAZAPURIN DERIVATIVES AS PHARMACEUTICAL COMPOUNDS
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
US7964732B2 (en) 2006-11-17 2011-06-21 Pfizer Inc. Substituted bicyclocarboxyamide compounds
AU2007329064C1 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag 2-Aminoquinolines as 5-HT(5A) receptor antagonists
MX2009009793A (en) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors.
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
JP2010528007A (en) * 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション Cyclopropylpyrrolidine orexin receptor antagonist
JP2010536872A (en) * 2007-08-22 2010-12-02 アラーガン、インコーポレイテッド Therapeutic quinoline and naphthalene derivatives
MX2010003001A (en) * 2007-09-27 2010-04-01 Hoffmann La Roche Quinoline derivatives as 5ht5a receptor antagonists.
PT2201012E (en) 2007-10-11 2014-09-04 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
CN101903384A (en) 2007-11-02 2010-12-01 沃泰克斯药物股份有限公司 [1H-Pyrazolo[3,4-B]pyridin-4-yl]-phenyl or -pyridin-2-yl derivatives as protein kinase Cθ inhibitors
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
JP2011513350A (en) * 2008-03-05 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー 2-Aminoquinolines
BRPI0910253A2 (en) * 2008-03-07 2015-09-29 Hoffmann La Roche 2-aminoquinoline derivatives
WO2009109502A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinolines
AU2009224760A1 (en) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag 2-Aminoquinolines as 5-HT5A receptor antagonists
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
CN105601619A (en) 2009-02-27 2016-05-25 埃姆比特生物科学公司 JAK kinase modulating compounds and methods of use thereof
EA201171098A1 (en) * 2009-03-02 2012-04-30 Сертрис Фармасьютикалз, Инк. 8-SUBSTITUTE QUINOLINES AND RELATED ANALOGUES AS SIRTUIN MODULATORS
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
KR20120051643A (en) * 2009-06-12 2012-05-22 쏘시에떼 스플리코 Compounds useful for treating premature aging in particular progeria
ES2575154T3 (en) * 2009-12-17 2016-06-24 Merck Sharp & Dohme Corp. Positive allosteric modulators of the quinoline amide M1 receptor
KR20120125267A (en) 2010-01-29 2012-11-14 베링거 인겔하임 인터내셔날 게엠베하 Substituted naphthyridines and their use as syk kinase inhibitors
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
AR082733A1 (en) * 2010-08-27 2012-12-26 Gruenenthal Gmbh 2-AMINO-QUINOLINA-3-CARBOXAMIDS REPLACED AS MODULATORS OF KCNQ2 / 3
CA2810024A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
HRP20191927T1 (en) 2011-04-01 2020-01-10 Astrazeneca Ab THERAPEUTIC TREATMENT
CA2834062A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
KR101986484B1 (en) 2011-07-26 2019-06-10 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinolines and their use as medicaments
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
PL2785349T5 (en) 2011-11-30 2023-01-30 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
EP3082807B1 (en) 2013-12-20 2018-07-04 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
ES2707125T3 (en) * 2014-10-31 2019-04-02 Genoscience Pharma Sas 2,4-diamino-quinoline substituted as new anticancer agents
SI3452465T1 (en) 2016-05-04 2021-04-30 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
US11091460B2 (en) * 2017-06-14 2021-08-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
EP3658560A4 (en) * 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND USES OF THESE LATEST
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
CN113166106B (en) * 2018-12-14 2022-07-08 正大天晴药业集团股份有限公司 Salt of Syk inhibitor and crystal form thereof
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
RS66978B1 (en) 2020-07-02 2025-07-31 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
EP4440570A1 (en) * 2021-12-01 2024-10-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Irap inhibitors for use in the treatment of inflammatory diseases
KR20240163688A (en) 2022-03-17 2024-11-19 인사이트 코포레이션 Tricyclic urea compounds as JAK2 V617F inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (en) * 1926-05-04 1933-03-17 Chem Ind Basel Process for the preparation of substituted quinolinecarboxamides
DE858698C (en) * 1951-02-09 1952-12-08 Basf Ag Process for the preparation of pyridine and quinoline derivatives
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (en) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2003078404A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Pyrimidine derivatives
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004081531A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Ligand analysis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
FR6103M (en) * 1967-02-22 1968-06-10
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2538388B1 (en) * 1982-12-24 1985-06-21 Pharmuka Lab NOVEL NAPHTHALENE- OR AZANAPHTHALENECARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
JPH05310702A (en) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd Anti-inflammatory agent, immunomodulating agent and quinoline-2,4-dicarboxylic acid diamide derivative
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
US6303593B1 (en) * 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU6051800A (en) * 1999-06-16 2001-01-02 University Of Iowa Research Foundation, The Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
CN100376557C (en) * 2001-05-21 2008-03-26 霍夫曼-拉罗奇有限公司 Quinoline derivatives as ligands for neuropeptide Y receptors
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0102858D0 (en) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (en) * 1926-05-04 1933-03-17 Chem Ind Basel Process for the preparation of substituted quinolinecarboxamides
DE858698C (en) * 1951-02-09 1952-12-08 Basf Ag Process for the preparation of pyridine and quinoline derivatives
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (en) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2003078404A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Pyrimidine derivatives
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004081531A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Ligand analysis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASEBE, M.; ET AL., TETRAHEDRON LETTERS, vol. 29, no. 48, 1988, pages 6287 - 6290, XP002445489 *
ILLUMINATI, G.; GILMAN, H., J. AM. CHEM. SOC., vol. 71, 1949, pages 3349 - 3351, XP002445491 *
SARGENT, H., J. AM. CHEM. SOC., vol. 68, 1964, pages 2688 - 2692, XP002445490 *
See also references of WO2004080463A1 *
WEISS, M.J.; HAUSER, C.R., J. AM. CHEM. SOC., vol. 71, 1949, pages 2026 - 2027, XP002445492 *

Also Published As

Publication number Publication date
CA2518398A1 (en) 2004-09-23
JP2006519846A (en) 2006-08-31
WO2004080463A1 (en) 2004-09-23
MXPA05009722A (en) 2006-03-09
EP1601357A1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS
EP1507541A4 (en) INHIBITORS AND METHODS OF USE THEREOF
EP1606285A4 (en) IDO INHIBITORS AND METHODS OF USE THEREOF
EP1691812A4 (en) GTPASE INHIBITORS AND METHODS OF USING SAME
EP1603567A4 (en) TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE
EP1723227A4 (en) NICOTINAMIDE RIBOSIDE KINASE COMPOSITIONS AND METHODS OF USE
EP1831207A4 (en) AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
EP1644323A4 (en) HISTONE DESACETYLASE INHIBITORS AND METHODS OF USE
IS7599A (en) Heterocyclic kinase inhibitors
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHODS OF USE
EP1603568A4 (en) ISOQUINOLINE DERIVATIVES AND METHODS OF USE
MA29029B1 (en) THIADIAZOLE COMPOUNDS AND METHODS OF USE
ATE359787T1 (en) CONTROLLED SYNTHESIS OF ZIPRASIDONE
EP1855833A4 (en) PLASMAS AND METHODS OF USE
PL376789A1 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
NL1027811A1 (en) Heterocyclic amines as inhibitors of 11-hydroxy-steroid-dehydrogenase type 1.
EP1706791A4 (en) PHOTORESIN COMPOSITIONS AND METHODS OF USE
ATE375336T1 (en) TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
EP1913112A4 (en) SUPPORTING AGENT AND METHODS OF USE
EP1722797A4 (en) ISOQUINOLINE DERIVATIVES AND METHODS OF USE
DK1531819T3 (en) Use of ikappab kinase inhibitors in pain management
EP1476150A4 (en) CARBOXYFULLERENES AND METHODS OF USE THEREOF
EP1534268A4 (en) INHIBITORS OF TYROSINE KINASE
EP1638513A4 (en) HIGHLY UNSAPINABLE SUBSTANCES AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077021

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070830

17Q First examination report despatched

Effective date: 20080603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100529

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077021

Country of ref document: HK